Pegfilgrastim biosimilar - Hospira

Drug Profile

Pegfilgrastim biosimilar - Hospira

Alternative Names: HSP-130; Pegylated filgrastim - Hospira; PF-06881894

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hospira
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Febrile neutropenia
  • Phase I Neutropenia

Most Recent Events

  • 09 Nov 2017 Phase-I clinical trials in Neutropenia (In volunteers) in USA (SC) (NCT03273842)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Neutropenia in United Kingdom (SC, Injection)
  • 05 Oct 2017 Pfizer completes a phase I/II trial in Febrile neutropenia in Spain and Hungary (SC) (NCT02650193)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top